Expert opinion about the “three months to live” prognosis Scottish physicians gave Abdelbaset Ali Mohmed al-Megrahi in August 2009. September 29, 2010
“Based on the medical report issued by the Scottish authorities, I believe that three-month prognosis was medically unjustifiable. Any physician with any training or experience in treating prostate cancer would have known that a three month prognosis simply could not be made based on Mr. al-Megrahi’s clinical situation at the time of diagnosis, the treatment received and the response to that treatment. Moreover, medical anomalies regarding his care – especially the use of chemotherapy – call into question how the three month prognosis was determined…………….
Mr. al-Megrahi’s release on compassionate grounds appears to have erred in two fundamental ways. First, we now know that Mr. al-Megrahi received chemotherapy in Scotland, which Scottish cancer specialists would have known was going to extend his life on average 17 or 19.2 months, depending on which of these well done, large, well known studies you wish toconsider. Even if Mr. al-Megrahi didn’t receive chemotherapy in Scotland and he was just planning on receiving such, he would still live on average 17 or 19.2 months beyond the starting date when he did receive chemotherapy upon his return to Libya. Again, Scottish cancer specialists would have known this from medical research dating from 2004.”
Dr. Mohler’s entire testimony can be read at:
Testimony – Dr. James Mohler Senate Committee on Foreign Relations
The release of al-Megrahil is an insult to the memory of the individuals who died in the terrorist attack, to their families and to the entire world. The release also contributes to the misunderstanding of the seriousness of this disease.
Joel T. Nowak, M.A., M.S.W.